Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 29, 2019
Finance
All eyes on new modality launches, cancer and rare disease data in 3Q19
Investors to watch new modality launches and cancer and rare disease data in a light 3Q19
BioCentury | Jul 6, 2018
Emerging Company Profile
Tethering bleeding risk
Tetherex’s antithrombotic therapy could reduce or eliminate risks of bleeding
BioCentury | Jun 22, 2018
Targets & Mechanisms
T cell balancing act
The latest debate in CAR T is whether CD8+ or CD4+ cells play the bigger role
BioCentury | Oct 26, 2017
Translation in Brief
Transient nanotargeting
mRNA-loaded nanoparticles transiently modify therapeutic cells simply and safely
BioCentury | Jun 9, 2017
Regulation
New SOC in sickle cell?
How Emmaus’ Endari could form the backbone of future sickle cell therapy
BioCentury | Jul 28, 2016
Tools & Techniques
Best of both worlds
Why NKT cells could help or even upstage CAR T cells
Items per page:
1 - 10 of 38